Status:
COMPLETED
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or analogs, which rely on the gastrointestinal hormones that are part of the incretin system for the treatment of ...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes
- Metformin monotherapy \> 12 weeks
- Hemoglobin A1c (HbA1c) \> 6.5 % and \< 9.0 %
- Body mass Index (BMI) 19-35 (kg/m²)
Exclusion
- acute diseases at randomization
- kidney diseases with creatinin \> 120 µmol/l, glomerular filtration rate (GFR) \<50 ml/min
- contraindication for Gliptins or glucagon-like-peptide-analogues according to the respective Summary of Product Characteristics (SmPC)
- previous use of dipeptidyl peptidase-4-inhibitors and GLP-1-mimetics
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT01518101
Start Date
January 1 2012
End Date
October 1 2012
Last Update
February 27 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Völlkingen, Germany, Germany, 66333
2
Novartis Investigative Site
Berlin, Germany, 10115
3
Novartis Investigative Site
Berlin, Germany, 13055
4
Novartis Investigative Site
Dortmund, Germany, 44137